Patients with urologic cancer and other nonurologic malignancies: analysis of a sample and review of the literature

Mydlo, Jack H.; Gerstein, Matthew

doi:10.1016/s0090-4295(01)01394-2

Cited by 30 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sekonder tümörler genellikle daha agresif, tedaviye rezistan ve erken metastaz yapma potansiyelinde olduğu için daha agresif tedavi stratejilerine ihtiyaç duyulmaktadır (4). Bir çalışmada ürologların tercihi sıklıkla lojistik ve topografik olarak uygun senkron tümörlerde eşzamanlı rezeksiyon yönünde olmuştur (73). İki tümörden hangisi daha agresifse öncelikle onun rezeke edilmesi önerilmektedir (73).…”

Section: Multipl Primer Kanserlerde Tedavi Ve Prognozunclassified

“…Bir çalışmada ürologların tercihi sıklıkla lojistik ve topografik olarak uygun senkron tümörlerde eşzamanlı rezeksiyon yönünde olmuştur (73). İki tümörden hangisi daha agresifse öncelikle onun rezeke edilmesi önerilmektedir (73). Tedavi yanında davranışsal risk faktörlerinin modifikasyonu ile MPK önlenmesi esastır (74).…”

Section: Multipl Primer Kanserlerde Tedavi Ve Prognozunclassified

See 1 more Smart Citation

Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients

Dirim¹,

Özkardeş²,

Hasırcı³

2016

uob

View full text Add to dashboard Cite

GirişMultipl primer kanserler (MPK) ilk olarak 1889 yılında Billroth tarafından farklı histolojide, farklı organda ve farklı zaman aralığında ortaya çıkan tümörler olarak tanımlanmıştır (1). Bu tanımlama sistemi Warren ve Gates (2) tarafından 1932 yılında modifiye edilerek günümüzde kullanılan şeklini almıştır. Güncel tanımlamaya göre multipl primer tümörlerde olması gereken üç özellik (a) her tümörün klinik ve histolojik özellikleriyle malign olduğunun ortaya konulması; (b) her birinin histolojik olarak farklı tümörler olması; (c) herhangi bir tümörün diğerinin nüksü ya da metastazı olmadığının gösterilmesi şeklinde belirlenmektedir.İlk primer tümör genellikle indeks tümör olarak da adlandırılır. Çoklu primer tümörler senkron veya metakron tümörler olmak üzere iki grupta değerlendirilmektedir. Ancak senkron ve metakron tümör tanımı için bir uzlaşı söz konusu değildir. SEER (Surveillance, Epidemiology, and End Results) ölçütlerine göre ilk tümör tanısından itibaren iki ay içerisinde yeni tanı konmuş kanserler için senkron, iki aydan sonrası için metakron tanımının kullanılması önerilmektedir (3). İki aydan daha kısa sürede ortaya çıkan tümörler için bazı çalışmalarda simültane tümör terimi de kullanılmıştır (4). Moertel (5), yeni bir tanımlama getirerek ikincil tümör, indeks tümör tanısından itibaren altı ay içerisinde görülürse senkron, altı aydan sonra The improvements in cancer treatment prolonged survival in patients. Despite this survival benefit, chemotherapies, radiotherapies or combination therapies, and continuing exposure to the same carcinogenic agents may lead to secondary cancers. Multiple primary neoplasm is described as multiple tumors in a single patient posing distinct individual malignant characteristics with definite exclusion of one tumor is the metastasis of the other. According to the time of onset, these are considered to be synchronous or metachronous tumors. While synchronous tumors often occur due to carcinogen exposure, metachronous tumors often develop after treatments such as radiotherapy. Although the cause and developmental mechanisms of multiple primary tumors are not clear, several factors including immune deficiency, genetic instability, increased use of systemic chemotherapy and radiotherapy, increased survival, elderliness, and smoking have been implicated. The two developmental hypotheses in development of multiple primary tumors appear as field cancerization and common clonal origin. Multiple primary tumors often involve respiratory, gastrointestinal, and genitourinary systems. Transitional cell carcinoma of the urinary bladder may also rise as part of synchronous or metachronous multiple tumors. We still lack large scale studies relevant to the treatment of multiple primary cancers. Close follow-up in primary malignant tumor patients is of extreme importance for the risk of secondary cancers. Keywords: Multiple primary tumor, synchronous and metachronous tumors, secondary tumor, bladder cancer Kanser tedavisindeki gelişmeler kanserli hastalarda sağkalımı uzatmaktadır. Ancak...

show abstract

Section: Multipl Primer Kanserlerde Tedavi Ve Prognozunclassified

Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients

Dirim¹,

Özkardeş²,

Hasırcı³

2016

uob

View full text Add to dashboard Cite

show abstract

“…A genetic predisposition, which involves mutations in genes that have been shown to be recurrently mutated in specific cancers, has been postulated as a cause for MPC (4,5). Other possibilities include the accumulation of free radicals, mistakes in DNA replication, and the reduced function of lipid-laden macrophages leading to impaired host immune surveillance (4).…”

Section: Introductionmentioning

confidence: 99%

“…Other possibilities include the accumulation of free radicals, mistakes in DNA replication, and the reduced function of lipid-laden macrophages leading to impaired host immune surveillance (4). The increased detection of MPC and potentially synchronous tumors may be attributed to the increased use of advanced diagnostic techniques (4,6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synchronous papillary urothelial carcinoma of the bladder and squamous cell carcinoma with sarcomatoid differentiation: A case report

et al. 2016

View full text Add to dashboard Cite

Abstract. The incidence rate of multiple primary tumors is 37% in all types of cancer. A patient diagnosed with primary cancer is 1.29 times more likely to develop an additional primary cancer when compared with the general population. Furthermore, in patients diagnosed with primary cancer, the possibility of a secondary malignancy in the same or different organ is increased. Following the identification of a secondary tumor, the risk of relapse or metastasis must be considered. The present study reports the case of a 76-year-old man who was admitted to Sakarya University Training and Research Hospital (Sakarya, Turkey) with swelling of the head, which had been apparent for 15 days. An excisional biopsy of the temporal region was performed and was used to diagnose the patient with synchronous squamous cell carcinoma with sarcomatoid differentiation of the scalp. The patient was referred to the Department of Plastic Surgery (Sakarya University Training and Research Hospital) for resection; however, he refused treatment and was subsequently discharged. To the best of our knowledge, this patient represents the first case of synchronous skin malignancy and urothelial carcinoma of the bladder to be reported in the literature. IntroductionMultiple primary cancers (MPCs) occur at a rate of 37% in all types of cancer (1). A patient with cancer is 1.29 times more likely to develop an additional primary cancer when compared with the risk of cancer in the general population (1). Synchronous tumors are defined as primary tumors that are diagnosed at the same time or within 6 months of each other, while primary tumors diagnosed 6 months after the initial primary tumor are defined as secondary or metachronous cancer (2). Secondary primary tumors most commonly occur in the lungs (27.6%), head and neck (20.3%), and urinary system (10.4%) (3).A genetic predisposition, which involves mutations in genes that have been shown to be recurrently mutated in specific cancers, has been postulated as a cause for MPC (4,5). Other possibilities include the accumulation of free radicals, mistakes in DNA replication, and the reduced function of lipid-laden macrophages leading to impaired host immune surveillance (4). The increased detection of MPC and potentially synchronous tumors may be attributed to the increased use of advanced diagnostic techniques (4,6). At present, there is no consensus on treatment recommendations for synchronous tumors. The treatment of synchronous tumors is dependent on the tumor's histological subtype, location, and stage (7). The surgical preference is for resection of both tumors simultaneously, whilst modification of behavioral risk factors may prevent the occurrence of MPCs (4).In the present study, a rare case of synchronous bladder cancer and squamous cell carcinoma with sarcomatoid differentiation of the scalp was reported. Case reportA 76-year-old man was admitted to Sakarya University Training and Research Hospital (Sakarya, Turkey) in March 2014 with swelling of the head, which had been apparent for 15 da...

show abstract

Association Between Colorectal Cancer and Urologic Cancers

Calderwood¹,

Huo²,

Rubin³

2008

Arch Intern Med

View full text Add to dashboard Cite

Background: Different types of urologic cancers have been associated with colorectal cancer (CRC) in hereditary nonpolyposis CRC , but it is still unknown whether there is an association between urologic cancer and CRC in the general population. We sought to quantify the risk for CRC after urologic cancer and the risk for urologic cancer after CRC in patients without known genetic syndromes. Methods: We performed a retrospective cohort analysis of the Surveillance, Epidemiology, and End Results program database from 1973 to 2000. Standard incidence ratios (SIRs) of observed to expected cases of invasive CRC were calculated for each urologic cancer site based on age, sex, ethnicity, and calendar year of diagnosis. Similar analysis was performed to determine the SIRs of urologic cancers in patients with previous CRC. Results: Overall, the risk for CRC was increased among patients with previous ureteral cancer (SIR, 1.80; 95% confidence interval [CI], 1.46-2.20) and renal pelvis cancer (SIR, 1.44; 95% CI, 1.20-1.72). This risk was great

show abstract

Patients with urologic cancer and other nonurologic malignancies: analysis of a sample and review of the literature

Cited by 30 publications

References 25 publications

Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients

Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients

Synchronous papillary urothelial carcinoma of the bladder and squamous cell carcinoma with sarcomatoid differentiation: A case report

Association Between Colorectal Cancer and Urologic Cancers

Contact Info

Product

Resources

About